In this one page overview from Clinical Care Options Oncology March 2015 (free membership), Dr Sharman explains how he categorises fit and otherwise healthy patients into low, intermediate and high treatment risk categories and chooses what he considers is the appropriate treatment for each category:
Of particular note: "Those patients with the most favorable risk profile include those with IgHV-mutated CLL without del(17p) or del(11q) by FISH analysis and without mutations in TP53, SF3B1, and NOTCH1 by sequencing analysis. This subset represents 20% of all treated patients; when treated with FCR the progression-free survival rate in this group at 8 years approaches 70% to 80%. Although many patients with CLL are not suitable for intensive chemoimmunotherapy with FCR, this population likely derives the best outcome with this treatment." (My emphasis)
Personally, I think Dr Sharman would have been disappointed with the minimal discussion his article generated.